Cited by 92Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver physiology and pathology

Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH

Open access
Majzoub, Abdul M., Nayfeh, Tarek, Barnard, Abbey, Munaganuru, Nagambika, Dave, Shravan, Singh, Siddharth, Murad, Mohammad Hassan, Loomba, Rohit·2021·Alimentary Pharmacology & Therapeutics

Abstract

Summary: Background: Nonalcoholic steatohepatitis (NASH) is a common cause of chronic liver disease. There is a major need to understand the efficacy of different pharmacological agents for the treatment of NASH. Aim: To assess the relative rank‐order of different pharmacological interventions in fibrosis improvement and NASH resolution. Methods: A comprehensive search of several databases was conducted by an experienced librarian. We included randomised controlled‐trials (RCTs) comparing pharmacological interventions in patients with biopsy‐proven NASH. The primary outcome was ≥1 stage improvement in fibrosis. The secondary outcome was NASH resolution. Results: A total of 26 RCTs with 23 interventions met the eligibility criteria. Lanifibranor and obeticholic acid had the highest probability of being ranked the most effective intervention for achieving ≥1 stage of fibrosis improvement (SUCRA 0.78) and (SUCRA 0.77), respectively. For NASH resolution, semaglutide, liraglutide and vitamin E plus pioglitazone had the highest probability of being ranked the most effective intervention for achieving NASH resolution (SUCRA 0.89), (SUCRA 0.84) and (SUCRA 0.83), respectively. Lanifibranor, obeticholic acid, pioglitazone and vitamin E were significantly better than placebo in achieving ≥1 stage of fibrosis improvement. Conversely, semaglutide, liraglutide, vitamine E plus pioglitazone, pioglitazone, lanifibranor and obeticholic acid were significantly better than placebo in achieving NASH resolution. Conclusion: These data provide relative rank‐order efficacy of various NASH therapies in terms of their improvements in liver fibrosis and NASH resolution. Therapies that have been shown to improve NASH resolution may be combined with therapies that have an antifibrotic effect to further boost treatment response rate in future.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/apt.16583

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Gut-derived hormones such as GLP-1 receptor agonists, dual agonists, and the FGF-19 mimetic aldafermin are already in clinical use or advanced development for metabolic diseases.

    “Gut-derived hormones are already in clinical use for metabolic diseases (e.g. GLP-1 receptor agonists, such as semaglutide or liraglutide, GLP-1/GIP [glucose-dependent insulinotropic polypeptide] dual agonists, such as tirzepatide) or in advanced clinical development (e.g, GLP-1/glucagon dual agonists, such as cotadutide, or the FGF-19 mimetic aldafermin).11,45”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Majzoub, A. M., Nayfeh, T., Barnard, A., Munaganuru, N., Dave, S., Singh, S., Murad, M. H., & Loomba, R.
Affiliations
  • Conemaugh Memorial Medical Center (US)
  • Mayo Clinic (US)
  • University of California San Diego (US)
Corresponding author
Loomba, Rohit
Venue
Alimentary Pharmacology & Therapeutics
Publisher
Wiley
Published
2021-08-25
Volume
54
Issue
7
Pages
880-889
ISSN
  • 0269-2813 (ISSN-L)
  • 1365-2036
OpenAlex
W3193811807
Cited by
92
References
52
Citations by year
2026: 14 · 2025: 14 · 2024: 18 · 2023: 20 · 2022: 24 · 2021: 2
FWCI
2.44
Type
journal article
Language
en
Open access
Locations
  • Alimentary Pharmacology & Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
  • National Institute of Environmental Health Sciences (5P42ES010337)
  • National Center for Advancing Translational Sciences (5UL1TR001442)
  • National Institute of Diabetes and Digestive and Kidney Diseases (U01DK061734, R01DK106419, P30DK120515, R01DK121378, R01DK124318)
  • National Heart, Lung, and Blood Institute (P01HL147835)
  • National Institute on Alcohol Abuse and Alcoholism (U01AA029019)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords
nonalcoholic steatohepatitis, NASH resolution, lanifibranor, obeticholic acid, semaglutide, liraglutide, pioglitazone, vitamin E, antifibrotic agents
MeSH terms
Pioglitazone, Biopsy, Humans, Liver Cirrhosis, Vitamin E, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review